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INTEREST OF AMICUS CURIAE JAMES D. WATSON 
James D. Watson is the co-discoverer of the double helix structure of 
deoxyribonucleic acid (“DNA”).  For this discovery, he and his colleague, the late 
Francis Crick (along with the late Maurice Wilkins for related work), were 
awarded the Nobel Prize in Physiology or Medicine in 1962.  See James D. 
Watson, The Double Helix (1968). 
Throughout his career, Dr. Watson has been at the forefront of recombinant 
DNA research and advances in genetic engineering.  From 1956 until 1976, Dr. 
Watson was on the faculty of Harvard University, leading the effort to focus the 
biology department on the then-emerging field of molecular biology.  Starting in 
1968, Dr. Watson was the director of Cold Spring Harbor Laboratory (“CSHL”).  
From 1994 to 2004, he served as the president of CSHL, and from 2004 until 2007, 
he was CSHL’s chancellor.  Dr. Watson is now Chancellor Emeritus of CSHL. 
Of particular pertinence to the present appeal is Dr. Watson’s role in the 
Human Genome Project.  In 1988, Dr. Watson was appointed Associate Director 
for Human Genome Research of the National Institutes of Health (“NIH”) and, in 
1989, Director of the National Center for Human Genome Research at the NIH.  In 
these positions, Dr. Watson lead the public effort to sequence the human genome. 
Given the significance of the issue at hand, Dr. Watson wishes to write 
directly to the Court. 
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ARGUMENT 
I. BECAUSE HUMAN GENES ARE UNIQUE AND CONVEY 
INFORMATION ABOUT THE ESSENCE OF BEING HUMAN, 
THEY SHOULD NOT BE PATENTED 
I have read through the various opinions issued in this case.1  Although the 
opinions admirably describe the scientific details of DNA and human genes, what 
the Court misses, I fear, is the fundamentally unique nature of the human gene.  
Simply put, no other molecule can store the information necessary to create and 
propagate life the way DNA does.  It is a chemical entity, but DNA’s importance 
flows from its ability to encode and transmit the instructions for creating humans.  
Life’s instructions ought not be controlled by legal monopolies created at the whim 
of Congress or the courts. 
Even before DNA’s structure was revealed, many scientists recognized the 
importance of a cell’s chromosomes (which are composed of DNA) to the 
propagation of life.  In 1944, Erwin Schrödinger, a Nobel Prize-winning physicist, 
wrote a small book titled What Is Life?  In it, he reasoned that chromosomes were 
the genetic information bearers.  Schrödinger thought that, because so much 
information must be packed into every cell, the information must be compressed 
into “hereditary code-script” embedded in the molecular fabric of the 
                                                 
1 I have also read the Supreme Court’s decision in Mayo v. Prometheus, although 
its opaqueness must leave many attorneys wondering if it adds anything at all to 
the issue of whether human genes ought to be patented.   
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chromosomes.  At the time, this was an untested hypothesis; most biologists 
thought that proteins would be identified as the bearers of genetic instruction.  
Eventually, chemical techniques advanced, and scientists confirmed that the 
chromosomes contained our genes.  
As it turned out, the secret to DNA’s ability to create life is its double helical 
structure, along with its information-coding sequences.  Francis Crick and I 
published the first correct structure of DNA in 1953.  J.D. Watson & F.H.C. Crick, 
A Structure for Dexoyribose Nucleic Acid, 171 Nature 737 (1953).2  The double-
helical structure epitomized elegance in simplicity.  From a chemical perspective, 
DNA is little more than two strands of a nucleotide polymer wound together in a 
double helix formation.  The nucleotide polymer consists of various sequences of 
A, T, G, and C bases.  The helical structure has two strands, one complementary to 
the other.  
As soon as Francis and I deciphered the structure, we immediately 
understood its significance.  With a hint of more to come, we wrote in our article 
that “[i]t has not escaped our notice that the specific pairing we have postulated 
immediately suggests a possible copying mechanism for the genetic material.”  
The double helix structure confirmed DNA’s role as the genetic carrier and created 
                                                 
2 At the time, we were in a tight race with Linus Pauling (soon to be a Nobel 
laureate in chemistry).  Fortunately for us, Pauling concluded that DNA was a 
triple helix—an erroneous conclusion ironically based on a chemical error. 
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the possibility of almost limitless information storage.  The various sequences of 
bases could be translated by a cell’s machinery, and that information would be 
used to create new proteins for the cell.3   
Later scientists discovered that certain DNA sequences controlled the 
expression of other genes.  One of the earliest discovered of these control 
sequences was the “TATA box.”  The TATA box contains the core DNA sequence 
5’-TATAAA-3’ or a similar variant.  Specific proteins can bind to this sequence, 
which promotes the transcription of other specific genes.  Extracted from the 
chromosome, a nucleic acid molecule having the TATAAA sequence has little, 
physically inherent value.  Its significance arises because that sequence is useful 
information to the cell’s genetic machinery.  The TATAAA sequence leads to the 
expression of genes that affect the cell and ultimately our human experience.   
The terminology of DNA underscores DNA’s informational role in life.  In a 
living cell, DNA is used to make RNA, and then RNA is used to make 
polypeptides, i.e., protein.  The first step—DNA to RNA—is called transcription.  
The second step—RNA to proteins—is called translation.  Both words connote the 
conveyance of information.  The information encoded by a human gene is first 
                                                 
3 Amusingly, after I gave my first presentation of our DNA structure in June 1953, 
Leó Szilárd, the Hungarian physicist and inventor of the nuclear chain reaction, 
asked whether I would patent the structure.  That, of course, was out of the 
question. 
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transcribed into RNA (DNA and RNA are similar molecules, thus similar 
languages, so the genetic information is merely transcribed from one format to 
another).  Then, the genetic information is translated from RNA into protein.  
(RNA and protein are different biochemical “languages,” hence translation).  The 
entirety of the DNA machinery focuses on transferring and utilizing the genetic 
information.  
When cells replicate, they make copies of the genetic code for the progeny 
cells.  New strands of DNA are synthesized in a process analogous to the way 
scriveners of years past would copy legal documents.  Just as scriveners would 
copy legal documents word by word, a cell copies the DNA molecule letter by 
letter (A, G, T, or C).  And just as scriveners proofread their work, the DNA 
polymerase—the enzyme that replicates DNA—has a built-in proofreading 
mechanism.  But as with all proofreading, the system is not perfect, and errors 
occur.  “Typographical” errors with DNA replication can lead to genetic 
mutations—which can cause devastating diseases or can lead to evolutionary 
improvements.   
To this day, we continue to learn how human genes function.  We estimate 
that humans have approximately 22,000 genes.  We have yet to fully understand 
the functions of all human genes, but this lack of understanding is further reason 
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that scientists should be permitted to experiment on human genes free from any 
threat of patent infringement.   
The social history of human genes also reveals DNA’s informational 
uniqueness.  In the early part of the twentieth century, many in society believed 
that the answers to all of society’s ills resided in the human genome.  From that 
belief grew the eugenics movement—an ill-fated movement founded on an 
incomplete understanding of genetics. 
Even the legendary Supreme Court justice Oliver Wendell Holmes 
misunderstood the role of genes in human development.  In the landmark case of 
Buck v. Bell, 274 U.S. 200, 207 (1927), Justice Holmes expressed a view about 
genetics that prevailed during his time: 
It is better for all the world, if instead of waiting to execute degenerate 
offspring for crime, or to let them starve for their imbecility, society 
can prevent those who are manifestly unfit from continuing their 
kind. . . .  Three generations of imbeciles are enough. 
We now know that many factors affect a person’s mental acuity, genes being some 
of them.  But Justice Holmes and other supporters of the eugenics movement could 
not appreciate, at that time, the precise role of the human gene.   
In years to come, with the right advances in genetic engineering, we may 
well be able to treat or rectify mental disabilities and physical diseases which today 
are deemed incurable.  Such hope is all the more reason that scientific research on 
human genes should not be impeded by the existence of unnecessary patents.  
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More importantly, we would not want one individual or company to monopolize 
the legal right to the beneficial information of a human gene—information that 
should be used for the betterment of the human race as a whole. 
By the 1970s, the public’s perception of DNA had reached its nadir.  Far 
from being viewed as the vindicator of the wrongfully accused—as the public sees 
it today—recombinant DNA technology was considered by many to be inherently 
dangerous.  Indeed, various interest groups wanted to ban recombinant DNA 
research.4  Ironically, this hysteria seemed to begin after I participated in the first 
scientific discussions exploring whether proposed regulations on DNA research 
were necessary (at the Gordon Research Conference of Nucleic Acids in June 
1973).  Unfortunately, the initial ruminations mutated into full-fledged proposed 
restrictions, issued from the Asilomar Conference in February 1974.  Later, as the 
hysteria increased, the National Institutes of Health (“NIH”) enacted regulations 
governing recombinant DNA technology.  The public discourse reached such a 
fevered pitch that, in the summer of 1976, the Cambridge City Council declared a 
three-month moratorium on recombinant DNA research in the city of Cambridge—
and therefore at Harvard University and the Massachusetts Institute of Technology.  
                                                 
4 I describe much of this history in one of my books.  See James D. Watson & John 
Tooze, The DNA Story: A Documentary History of Gene Cloning (1981). 
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I, of course, did not favor these restrictions.  At one point, I had to defend 
recombinant DNA research from the attacks of the actor Robert Redford, who, 
along with the Environmental Defense Fund, raised money to stop experiments 
with recombinant DNA.  See James D. Watson, The Nobelist vs. The Film Star: 
DNA Restrictions Attacked, Washington Post, May 14, 1978, at D1.  Eventually, 
reason and objectivity prevailed, and scientists were free to conduct their 
recombinant DNA research without absurd regulations. 
My point with this overly brief and incomplete history of recombinant DNA 
research is to illustrate how the major controversies associated with human genes 
have arisen because human genes are much more than chemical compounds.  The 
myopic viewpoint thinks of a human gene as merely another chemical compound, 
composed of various bases and sugars.  But history and science teach us otherwise.  
A human gene, which is a product of nature, is useful because it conveys vital 
information.  The human genome’s ability to be our instruction book on life 
distinguishes it from other chemicals covered by the patent laws.  No other 
molecule carries the information to instruct a human zygote to become a boy or a 
girl, a blonde or brunette, an Asian, African, or Caucasian.   
II. THE HUMAN GENOME PROJECT WAS INTENDED TO BENEFIT 
ALL, NOT JUST SELECT COMPANIES 
In addition to understanding the uniqueness of human DNA, I hope that an 
awareness of the Human Genome Project’s history will guide the Court to the 
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correct decision that human genes, as products of nature, should not be patented.  
The Human Genome Project was started not to increase the profits of select 
companies but to expand the our understanding of the human genome and make 
this information available to all scientists.  
The genesis of the Human Genome Project dates to the mid-1980s, when the 
dual technological advances of recombinant DNA and computers opened the door 
to deciphering the human genome.  In June 1986, I organized a special session at 
Cold Spring Harbor Laboratory to discuss the beginnings of what would become 
the Human Genome Project.  At that time, the U.S. Department of Energy had also 
begun to focus on sequencing the genome.  Other eminent scientists joined the 
early effort, including Bruce Alberts, Sydney Brenner, and David Botstein.  
Eventually, we published our report (from the National Academy of Sciences) 
making the case for sequencing the human genome.  With the support of James 
Wyngaarden, then-head of NIH, and many others, the Human Genome Project 
became reality. 
In May 1988, I was appointed Associate Director for Human Genome 
Research of NIH (and later, in 1989, became NIH’s Director of the National Center 
for Human Genome Research).  In these positions, my role was to oversee a 
multimillion dollar budget and to organize what had become an international effort 
to map the human genome.  The United States was directing the project and carried 
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out half of the work, while the rest was done mainly in the United Kingdom, 
France, Germany, and Japan.   
Even at the early stages of the project, we were concerned about the issue of 
patenting human genes.  Most, although not all, eminent scientists recognized that 
human genes should not be monopolized by patents.  I believed at the time—and 
continue to believe—that the issue of patenting human genes went to the very crux 
of whether the information encoded by human DNA should be freely available to 
the scientific community.  Some twenty years ago, I explained that patenting 
human genes was lunacy, and I was not a lone voice.   
Sadly, and to the detriment of scientific research, my view did not control 
the policy decisions of NIH, which had filed for numerous patents covering human 
genes.  Even more egregious were the types of patents being filed on human genes.  
Many of NIH’s patents described only small portions of a gene.  For example, in 
June 1991, an NIH official had urged Craig Venter, who at the time was working at 
NIH, to file patent applications on several hundred new DNA sequences, even 
though, in many instances, neither Venter nor NIH had any inkling of what those 
sequences did.  The following year, Venter listed over 2,000 more sequences in his 
patent applications, still having no clue about the function of those sequences.   
I expressed my objections to NIH management, but to no avail.  To me, it 
was clear that the goal of the Human Genome Project was to map and publish the 
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human genome sequence for the scientific community.  As the then-leader of the 
project, I felt a particular obligation to do what I could.  In my view,  
[t]he Human Genome Project is much more than a vast roll call of As, 
Ts, Gs, and Cs: it is as precious a body of knowledge as humankind 
will ever acquire, with a potential to speak to our most basic 
philosophical questions about human nature, for purposes of good and 
mischief alike. 
James D. Watson, DNA: The Secret of Life 172 (2003). In 1992, I publicly 
opposed NIH’s decision to patent human genes.  As a result, I was left with no 
choice and was forced to resign from NIH that year.  Patenting human genes was 
not necessary to complete the Human Genome Project.  Indeed, the international 
effort was proceeding on schedule without any need to file patent applications on 
human genes.  
Less than fifteen years after its start, the Human Genome Project, along with 
Celera Genomics, achieved success.  On June 26, 2000, President Bill Clinton and 
Prime Minister Tony Blair announced that the two groups had finished a working 
draft, which was published for the public in February 2001.  Gaps in the rough 
draft were filled in by 2003—fifty years after Crick and I published the structure of 
DNA.  Scientists have used the data to estimate that humans have about 22,000 
genes—in some sense a surprisingly small number compared to other organisms. 
The Human Genome Project was a multi-agency, international effort.  It was 
funded in large part by taxpayer money, and the primary expectation was that the 
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information derived from the sequenced human genes would be available for all 
scientists to use.  Unfortunately, a decade later, private companies are still trying to 
unnecessarily restrict access to human genes and the information encoded in those 
genes.  This situation burdens all of society.  Other scientists involved in the 
Human Genome Project continue to warn about the harms caused by patenting 
human genes.  For instance, John Sulston, who received the 2002 Nobel Prize in 
Physiology or Medicine, headed the British effort of the Human Genome Project.  
He has explained that “many human genes have patent rights on them and this is 
going to get in the way of treatment unless you have a lot of money.”5   
III. PATENTS ON HUMAN GENES ARE NOT NECESSARY, BUT IF 
THEY ARE GRANTED, COMPULSORY LICENSES SHOULD BE 
REQUIRED TO ENSURE FAIR ACCESS 
As a third point, lawyers and judges misunderstand scientific research when 
they contend that patent protection is necessary to encourage scientists to discover 
human genes.  A scientist does not—and should not—expect to obtain a legal 
monopoly controlling the information encoded by human genes.  And the average 
scientist should not expect a windfall simply for revealing the sequence of DNA 
bases that encode various genes.  Research on human genes is one of those rare 
endeavors which should be—and is done—with the understanding that, although 
                                                 
5 See Alok Jha, Human Genome Project Leader Warns Against Attempts to Patent 
Genes, The Guardian, June 24, 2010, at http://www.guardian.co.uk/science/2010/ 
jun/24/human-genome-project-patent-genes. 
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inventions based on those genes may later be commercialized, the genes 
themselves are to be employed for the maximum benefits of humankind.   
Consider also whether a biotechnology or pharmaceutical company derives 
major revenue of human genes.  From what I have seen, the answer is generally no.  
Most biotechnology and pharmaceutical companies do not derive substantial 
revenue from selling or licensing human genes.  Rather, their primary revenue 
source is much more likely their selling pharmaceuticals or actual research tools.  
We should not be overly concerned that banning patents on human genes will 
cause a detrimental loss of revenue. 
Additionally, researchers are developing new medical diagnostic tools which 
often rely on the use of multiple genes.  For instance, investigators at the 
University of Washington have developed parallel gene sequencing methods for 
identifying of inherited mutations in breast and ovarian cancer genes.  See Tom 
Walsh, et al., Detection of Inherited Mutations for Breast and Ovarian Cancer 
Using Genomic Capture and Massively Parallel Sequencing, 107 Proceedings of 
the National Academy of Science USA 12,629 (2010).  This group’s approach uses 
multiple genes, not just the specific BRCA1 and BRCA2 genes in the Myriad 
patents, to estimate cancer risk.   
If each of the human genes used in a new multi-gene assay are subject to 
patents, I fear that useful tests requiring multiple human genes will be 
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unnecessarily delayed, become prohibitively expensive, or, worse yet, never be 
made available to patients at all.  For a new assay using hundreds of human genes, 
the sea of patents and patent applications would create hundreds, if not thousands, 
of individual obstacles to developing and commercializing the assay.  The best 
way, in my view, to resolve this problem is to eliminate the unnecessary patenting 
of human genes. 
If, for some reason, patents on human genes are deemed necessary, the next 
best, albeit imperfect, solution is to require those patent holders to license the 
patents to other researchers so that scientific progress is not obstructed.  This is 
often called a “compulsory license.”  In my view, a compulsory license can 
establish reasonable access to human genes and genetic information—which is 
what scientists in general want, had the lawyers and courts not complicated 
matters.  Reasonable access facilitates scientific and social progress.   
Compulsory licensing ensures that scientists and researchers will have 
reasonable access to human genes and genetic information.  Compulsory licensing 
will attenuate the negative consequences of the genetic monopolies created by 
patents.  Implementing a compulsory license protocol will also reduce the risk that 
a patient is denied access to life-saving medicines and technologies using human 
genes and the information encoded in the genes. 
Finally, I do not suggest that all patents relating to recombinant DNA
technology should be abolished. Scientists have developed many new inventions
based on recombinant DNA technology. And these inventions have contributed to
the progress of science and the success of our nation. But, as I have written before,
"[g]ood patents, I would suggest, strike a balance: they recognize and reward
innovative work and protect it from being ripped off, but they also make new
technology available to do the most good." James D. Watson, DNA: The Secret of
Life 122 (2003).
IV. RULE 29(c)(5) STATEMENT
No party's counsel authored this brief in whole or in part. No party, no
party's counsel, and no other person contributed money that was intended to fund
the preparation and submission of this brief.
V. CONCLUSION
For at least the reasons above, Dr. Watson respectfully asks the Court to
reconsider its opinion on the patentability of human genes.
Date: June 15, 2012
Respectfully submitted,
Matthew J. Do d
James H. Wallace, Jr.
WILEY REIN LLP
1776 K Street, N.W.
Washington, D.C. 20006
Attorneys for Amicus Curiae James D. Watson
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